ArticleCureus2026
Zone 3 Aggressive Retinopathy of Prematurity in a Near-Term Delivered Big Baby With a Birth Weight of 3,200 g.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aggressive retinopathy of prematurity (A-ROP) represents a severe, rapidly progressive variant of retinopathy of prematurity (ROP) that is most observed in extremely premature, low-birth-weight infants and usually involves the posterior zones. Its occurrence in near-term infants with normal birth weight, involving Zone 3, is rare. This report dwells upon such a rare occurrence. This is a case of a male baby born at 37 weeks' gestation with a birth weight of 3,200 g. The baby required a neonatal ICU (NICU) admission for 13 days for respiratory distress and seizures. At a postmenstrual age of 40 weeks, fundus examination revealed A-ROP in both eyes in Zone 3. After parental counseling, bilateral intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy with bevacizumab (one-third adult dose, 0.4 mg/0.015 mL) was administered. The infant showed rapid regression of plus disease and hemorrhages. Subsequent follow-ups demonstrated continued improvement, with complete retinal maturation by six months. At the final follow-up, the child had a mature retina, an unremarkable anterior segment, and a refraction of +0.50 DS/-2.00 DC × 180° in both eyes. This case highlights a rare presentation of A-ROP involving Zone 3 in a near-term, normal birth-weight infant. The potential role of postnatal factors, including respiratory distress management, in the development of A-ROP outside traditional risk profiles. The prognosis is good if the condition is treated promptly and there is no further systemic deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.